In vitro activity of panomycocin, a novel exo-β-1,3-glucanase isolated from Pichia anomala NCYC 434, against dermatophytes

Mycoses

Volumn 50, Issue 1, 2007, Pages 31-34

  Izgü, Fatih ^a   Altinbay, Demet ^a   Türeli, Akif Emre ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Antifungal activity; Dermatophytes; Exo 1,3 glucanase; Killer protein; Pichia anomala

Indexed keywords

1,3 BETA GLUCANASE; ANTIFUNGAL AGENT; GENE PRODUCT; NCYC 434 PROTEIN; PANOMYCOCIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DERMATOPHYTE; DRUG ACTIVITY; DRUG DETERMINATION; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME ACTIVITY; FUNGUS; FUNGUS ISOLATION; GROWTH INHIBITION; IN VITRO STUDY; MICROSPORUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRICHOPHYTON;

ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; GLUCAN 1,3-BETA-GLUCOSIDASE; MICROBIAL SENSITIVITY TESTS; MICROSPORUM; PICHIA; TRICHOPHYTON;

ARTHRODERMATACEAE; MICROSPORUM; PICHIA ANOMALA; TRICHOPHYTON;

EID: 33845974079     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01303.x     Document Type: Article

References (27)

1. Weitzman I, Summerbell RC. The dermatophytes. Clin Microbiol Rev 1995; 8: 240-59.
2. Carrillo-Munoz AJ, Gugllietta A, Palacin C et al. In vitro antifungal activity of sertaconazole compared with nine other drugs against 250 clinical isolates of dermatophytes and Scopulariopsis brevicaulis. Chemotherapy 2004; 50: 308-13.
3. Venkatesan P, Perfect JR, Myers SA. Evaluation and management of fungal infections in immunocompromised patients. Dermatol Ther 2005; 18: 44-57.
4. Fernandez-Torrez B, Carrillo AJ, Martin E et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001; 45: 2524-8.
5. Fernandez-Torres B, Inza I, Guarro J. In vitro activities of the new antifungal drug eberconazole and three other topical agents against 200 strains of dermatophytes. J Clin Microbiol 2003; 41: 5209-11.
6. Hossain AG, Ghannoum MA. New developments in chemotherapy for non-invasive fungal infections. Expert Opin Investig Drugs 2001; 10: 1501-11.
7. Bobek LA, Situ H. MUC 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action. Antimicrob Agents Chemother 2003; 47: 643-52.
8. Selitrennikoff CP. Antifungal proteins. Appl Environ Microbiol 2001; 67: 2883-94.
9. Schmitt MJ, Breinig F. The viral killer system in yeast: from molecular biology to application. FEMS Microbiol Rev 2002; 26: 257-76.
10. Passoth V, Fredlund E, Drufevors UA, Schnürer S. Biotechnology, physiology and genetics of the yeast Pichia anomala. FEMS Yeast Res 2006; 6: 3-13.
11. Bevan EA, Makower M. The physiological basis of the killer character in yeast. Proc 11th Int Cong Gene 1963; 1: 202-3.
12. Magliani W, Conti S, Gerloni M, Bertolotti D, Polonelli L. Yeast killer systems. Clin Microbiol Rev 1997; 10: 369-400.
13. Staib F. The green colour effect (GCE) of the killer strain Cryptococcus laurentii CBS 139 on Staib agar. Mycoses 1999; 42: 103-6.
14. Pfeiffer I, Golubev WI, Farlas Z, Kucsera J, Golubev N. Mycocin production in Cryptococcus aquaticus. Antonie Van Leeuwenhoek 2004; 86: 369-75.
15. Jijakli MH, Lepoivre P. Characterization of an exo-b-1,3-glucanase produced by Pichia anomala strain K, antagonist of Botrytis cinerea on apples. Phytopathology 1998; 88: 335-43.
16. Young TW, Yagiu M. A comparison of the killer character in different yeasts and its classification. Antonie Van Leeuwenhoek 1978; 44: 59-77.
17. Wickner RB. The killer double stranded RNA plasmids of yeast. Plasmid 1979; 2: 303-22.
18. Sangorrin MP, Zajonskovsky IE, Lopez CA et al. Killer behaviour in wild wine yeasts associated with Merlot and Malbec type musts spontaneously fermented from north western Patagonia (Argentina). J Basic Microbiol 2001; 41: 105-13.
19. Walker GM, McLeod AH, Hodgson VJ. Interactions between killer yeasts and pathogenic fungi. FEMS Microbiol Lett 1995; 127: 213-22.
20. Yap NA, Lopes B, Langridge P, Henschke PA. The incidence of killer activity of non-Saccharomyces yeasts towards indigenous yeast species of grape must: potential application in wine fermentation. J Appl Microbiol 2000; 89: 381-9.
21. Izgü F, Altinbay D. Isolation and characterization of the K5-type yeast killer protein and its homology with an exo-β-1,3-glucanase. Biosci Biotechnol Biochem 2004; 68: 685-93.
22. Izgu F, Altinbay D, Sertkaya A. Enzymic activity of the K5-type yeast killer toxin and its characterization. Biosci Biotechnol Biochem 2005; 69: 2200-6.
23. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
24. Clinical and Laboratory Standards Institute. Reference Methods for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standards. CLSI Document M38-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2002.
25. Marr KA, Rustad TR, Rex JH, White TC. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 1999; 43: 1383-6.
26. Fernandez-Torres B, Cabanes FJ, Carrillo-Munoz AJ et al. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 2002; 40: 3999-4003.
27. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician 2002; 65: 2095-102.